Compare · SEER vs WAT
SEER vs WAT
Side-by-side comparison of Seer Inc. (SEER) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SEER and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $36.64B, about 307.1x SEER ($119.3M).
- Over the past year, SEER is up 2.3% and WAT is up 22.5% - WAT leads by 20.2 points.
- SEER has been more active in the news (20 items in the past 4 weeks vs 8 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 8 for SEER).
- Company
- Seer Inc.
- Waters Corporation
- Price
- $2.18+0.00%
- $373.92+0.24%
- Market cap
- $119.3M
- $36.64B
- 1M return
- +28.24%
- +3.61%
- 1Y return
- +2.35%
- +22.54%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 1995
- News (4w)
- 20
- 8
- Recent ratings
- 8
- 25
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest SEER
- Director Nishar Dipchand sold $23,265 worth of shares (10,660 units at $2.18) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 59,044 units (SEC Form 4) to cover withholding tax
- SEC Form DFAN14A filed by Seer Inc.
- The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company’s Blatant Rewriting of History
- SEC Form 144 filed by Seer Inc.
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DEFA14A filed by Seer Inc.
- Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer’s Director Nominees
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DFAN14A filed by Seer Inc.
- The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.’s Proposal to Acquire Seer, Inc.
Latest WAT
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)
- Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
- Bernstein resumed coverage on Waters with a new price target
- SVP Waters Analytical Sciences Carpio Robert L Iii covered exercise/tax liability with 189 shares, decreasing direct ownership by 5% to 3,426 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Waters Corporation
- IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
- Piper Sandler initiated coverage on Waters with a new price target
- Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis